PATHEON背景：氧化应激增高和炎症在慢性阻塞性肺疾病（COPD）的发病机理中具有一定作用。具有抗氧化和抗炎作用的药物，如N-乙酰半胱氨酸可能是治疗COPD的有效方法。PANTHEON的目标是评估N-乙酰半胱氨酸能否降低COPD患者的急性加重率。

钟南山: PANTHEON is the largest, evidence-based study of long-term treatment with N-acetylcysteine (NAC) in COPD patients conducted to date. The main finding of this study is that 1-year of treatment with high dose NAC (600mg twice daily) was effective at reducing exacerbations in patients with COPD, especially in the earlier stage [GOLD II (moderate) of disease. NAC was well tolerated.

结合LANCET RESPIRATORY 2014最新PANTHEON STUDY，华西医院大内科主任文富强教授，为您讲解降低慢阻肺急性加重风险的临床研究新进展。